Naringin Mitigates LPS-induced Intestinal Barrier Injury in Mice.

Diaoyun Luo,Zhiqing Huang,Gang Jia,Hua Zhao,Guangmang Liu,Xiaoling Chen

DOI: https://doi.org/10.1039/d2fo03586c

IF: 6.3173

2023-01-01

Food & Function

Abstract:Naringin attenuates a LPS-induced jejunum barrier damage by decreasing the secretion of inflammatory cytokines and intestinal permeability, increasing the expression of tight junction protein-related genes and antioxidant capacity.

What problem does this paper attempt to address?

Naringin Exhibited Therapeutic Effects against DSS-Induced Mice Ulcerative Colitis in Intestinal Barrier–Dependent Manner

Ruige Cao,Xing Wu,Hui Guo,Xin Pan,Rong Huang,Gangqiang Wang,Jikai Liu

DOI: https://doi.org/10.3390/molecules26216604

IF: 4.6

2021-10-31

Molecules

Abstract:Naringin is a kind of multi-source food additive which has been explored broadly for its various biological activities and therapeutic potential. In the present study, the protective effect and mechanism of naringin on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) in mice were investigated. The results showed that naringin significantly alleviated DSS-induced colitis symptoms, including disease activity index (DAI), colon length shortening, and colon pathological damage. The tissue and serum secretion of inflammatory cytokines, as well as the oxidative stress, were decreased accordingly upon naringin intervention. Naringin also decreased the proteins involved in inflammation and increased the expression of tight junction (TJ) proteins. Moreover, naringin increased the relative abundance of Firmicutes/Bacteroides and reduced the content of Proteobacteria to improve the intestinal flora disorder caused by DSS, which promotes the intestinal health of mice. It was concluded that naringin can significantly ameliorate the pathogenic symptoms of UC through inhibiting inflammatory response and regulating intestinal microbiota, which might be a promising natural therapeutic agent for the dietary treatment of UC and the improvement of intestinal symbiosis.

chemistry, multidisciplinary,biochemistry & molecular biology
Mucoactive effects of naringin in lipopolysaccharide-induced acute lung injury mice and beagle dogs.

Yan Chen,Hao Wu,Yi-chu Nie,Pei-bo Li,Jian-gang Shen,Wei-wei Su

DOI: https://doi.org/10.1016/j.etap.2014.04.030

IF: 4.3

2014-01-01

Environmental Toxicology and Pharmacology

Abstract:•The mucoactive effect of naringin in pathological in vivo models was investigated.•Naringin exhibits mucoactive effects through multiple targets.•Naringin reduces of goblet cells hyperplasia and mucus hypersecretion.•Naringin promotes sputum excretion.
Naringin attenuates MLC phosphorylation and NF-κB activation to protect sepsis-induced intestinal injury via RhoA/ROCK pathway.

Zhiling Li,Ming Gao,Bingchang Yang,Huali Zhang,Kangkai Wang,Zuoliang Liu,Xianzhong Xiao,Mingshi Yang

DOI: https://doi.org/10.1016/j.biopha.2018.03.163

2018-01-01

Abstract:BACKGROUND:Sepsis is commonly associated with excessive stimulation of host immune system and result in multi-organ failure dysfunction. Naringin has been reported to exhibit a variety of biological effects. The present study aimed to investigate the protective effect of naringin on sepsis-induced injury of intestinal barrier function in vivo and in vitro. METHODS:Mice were randomly divided into 4 groups named sham (n = 20), CLP + vehicle (n = 20), CLP + NG (30 mg/kg) (n = 20) and CLP + NG (60 mg/kg) (n = 20) groups. Sepsis was induced by cecal ligation and puncture (CLP). H&E staining and transmission electron microscopy (TEM) were performed to observe intestinal mucosal morphology. ELISA was used to determine the intestinal permeability and inflammatory response in vivo and in vitro. Western blot and RhoA activity assay were performed to determine the levels of tight junction proteins and the activation of indicated signaling pathways. MTT assay was used to determine cell viability. RESULTS:Naringin improved survival rate of CLP mice and alleviated sepsis-induced intestinal mucosal injury. Furthermore, naringin improved impaired intestinal permeability and inhibited the release of TNF-α and IL-6, while increased IL-10 level in CLP mice and lipopolysaccharide (LPS)-stimulated MODE-K cells in a dose-dependent manner. Naringin increased the expression of tight junction proteins ZO-1 and claudin-1 via RhoA/ROCK/NF-κB/MLCK/MLC signaling pathway in vivo and in vitro. CONCLUSION:Naringin improved sepsis-induced intestinal injury via RhoA/ROCK/NF-κB/MLCK/MLC signaling pathway in vivo and in vitro.
Naringin Attenuates Acute Lung Injury in LPS-treated Mice by Inhibiting NF-κB Pathway.

Ying Liu,Hao Wu,Yi-chu Nie,Jia-ling Chen,Wei-wei Su,Pei-bo Li

DOI: https://doi.org/10.1016/j.intimp.2011.05.022

IF: 5.714

2011-01-01

International Immunopharmacology

Abstract:Naringin has been reported as an effective anti-inflammatory compound. We previously showed that naringin had antitussive effect on experimentally induced cough in guinea pigs. However, the effects and mechanism of naringin on lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice are not fully understood. In this study, our aim was to evaluate the anti-inflammatory activities of naringin on LPS-induced ALI in mice and clarify its underlying mechanisms of action. We found that in vivo pretreatment with naringin markedly decreased the lung wet weight to dry weight ratio, and led to significant attenuation of LPS-induced evident lung histopathological changes. Meanwhile, naringin significantly reduced bronchoalveolar lavage fluid (BALF) total cell and neutrophil (PMN) counts after LPS challenge. Furthermore, naringin inhibited myeloperoxidase (MPO: a marker enzyme of neutrophil granule) and inducible nitric oxide synthase (iNOS) activities in lung tissue and alleviated LPS-induced tumor neurosis factor-α (TNF-α) secretion in BALF in a dose-dependent manner. Additionally, Western blotting showed that naringin efficiently blunt NF-κB activation by inhibiting the degradation of IĸB-α and the translocation of p65. Taken together, these results suggest that naringin shows anti-inflammatory effects through inhibiting lung edema, MPO and iNOS activities, TNF-α secretion and pulmonary neutrophil infiltration by blockade of NF-κB in LPS-induced ALI.
Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice.

Hongyang Cao,Jiuxi Liu,Peng Shen,Jiapei Cai,Yuchang Han,Kunpeng Zhu,Yunhe Fu,Naisheng Zhang,Zecai Zhang,Yongguo Cao

DOI: https://doi.org/10.1021/acs.jafc.8b03942

IF: 6.1

2018-01-01

Journal of Agricultural and Food Chemistry

Abstract:Peroxisome proliferator-activated receptor γ (PPARγ) is an important member of the nuclear receptor superfamily. Previous studies have shown the satisfactory anti-inflammatory role of PPARγ in experimental colitis models, mainly through negatively regulating several transcription factors such as nuclear factor-κB (NF-κB). Therefore, regulating PPARγ and PPARγ-related pathways has great promise for treating ulcerative colitis (UC). In the present study, our objective was to explore the potential effect of naringin on dextran sulfate sodium (DSS) induced UC in mice and its involved potential mechanism. We found that naringin significantly relieved DSS-induced disease activities index (DAI), colon length shortening, and colonic pathological damage. Exploration of the potential mechanisms demonstrated that naringin significantly activated DSS-induced PPARγ and subsequently suppressed NF-κB activation. PPARγ inhibitor GW9662 largely abrogated the roles of naringin in vitro. Moreover, DSS induced the activation of mitogen-activated protein kinase (MAPK) and (NOD)-like receptor family pyrin domain containing 3 (NLRP3) inflammasome was inhibited by naringin. Tight junction (TJ) architecture in naringin groups was also maintained by regulating zonula occludens-1 (ZO-1) expression. These results suggested that naringin may be a potential natural agent for protecting mice from DSS-induced UC.
Protective Effects of Naringin Against Paraquat-Induced Acute Lung Injury and Pulmonary Fibrosis in Mice

Yan Chen,Yi-chu Nie,Yu-long Luo,Feng Lin,Yan-fang Zheng,Guo-hua Cheng,Hao Wu,Ke-jian Zhang,Wei-wei Su,Jian-gang Shen,Pei-bo Li

DOI: https://doi.org/10.1016/j.fct.2013.04.024

IF: 4.3

2013-01-01

Food and Chemical Toxicology

Abstract:The present study evaluates protective effects of naringin against paraquat (PQ)-induced acute lung injury (ALI) and pulmonary fibrosis in mice. Survival probability against PQ intoxication was tested by a single intraperitoneal injection of PQ. Results showed that survival rates of mice exposed to PQ only (50 mg/kg within 7 days) were much lower than that in mice daily treatment with NAC or naringin. Moreover, protection against PQ-induced ALI was tested by daily pretreatment mice with saline, NAC or naringin for 3 days before PQ (30 mg/kg, i.p.). Results showed that increase in leukocytes infiltration and overexpressions of TNF-α and TGF-β1 caused by 8h of PQ exposure were dose-dependently ameliorated by naringin. Furthermore, protection against PQ-induced pulmonary fibrosis was tested by pretreatment mice with PQ (20 mg/kg, i.p.), and then daily administration with saline, NAC or naringin for prolonged 21 days. Results showed that naringin of 60 and 120 mg/kg significantly reduced PQ-induced upregulations of TNF-α, TGF-β1, MMP-9 and TIMP-1, levels of pulmonary malonaldehyde and hydroxyproline, as well as pulmonary fibrosis deposition, while increased activities of SOD, GSH-Px and HO-1. These results indicated that naringin had effective protection against PQ-induced ALI and pulmonary fibrosis.
Naringin Exerts Therapeutic Effects on Mice Colitis: A Study Based on Transcriptomics Combined With Functional Experiments

Jianyi Dong,Yuanyuan Chen,Fang Yang,Weidong Zhang,Kun Wei,Yongjian Xiong,Liang Wang,Zijuan Zhou,Changyi Li,Jingyu Wang,Dapeng Chen

DOI: https://doi.org/10.3389/fphar.2021.729414

IF: 5.6

2021-08-24

Frontiers in Pharmacology

Abstract:Naringin has been shown to exert protective effects in an animal model of ulcerative colitis, but detailed mechanisms remain unclear. This study aimed to investigate function and signaling mechanisms underlying naringin-induced therapeutic effects on colitis. Two mouse models were established to mimic human Inflammatory bowel disease (IBD) by treating drinking water with dextran sodium sulphate or intra-colonic administration of 2, 4, 6-trinitrobenzene sulfonic acid. Transcriptomics combined with functional experiments were used to investigate underlying mechanisms. Colitis symptoms, including weight loss and high disease activity index were significantly reversed by naringin. The inflammatory response, oxidative reactions, and epithelial cell apoptosis that occur with colitis were also alleviated by naringin. After naringin treatment, transcriptomics results identified 753 differentially expressed mRNAs that were enriched in signaling pathways, including the neuroactive ligand-receptor interaction, calcium signaling, and peroxisome proliferator-activated receptor (PPAR) signaling. The naringin-induced alleviation of colitis was significantly inhibited by the PPAR-γ inhibitor BADGE. In IEC-6 and RAW264.7 cells incubated with lipopolysaccharide (LPS), NF-κB-p65, a downstream protein of PPAR-γ, was significantly increased. Naringin suppressed LPS-induced high expression of NF-κB-p65, which was inhibited by small interfering RNA targeting PPAR-γ. Our study clarifies detailed mechanisms underlying naringin-induced therapeutic effects on mice colitis, and PPAR-γ was found to be the main target of naringin by functional experiments both in vivo and in vitro . Our study supplies new scientific information for the use of naringin in colitis treatment.

pharmacology & pharmacy
Naringenin Prevents TNF-α-induced Gut-Vascular Barrier Disruption Associated with Inhibiting the NF-κB-mediated MLCK/p-MLC and NLRP3 Pathways

Jia Zhong,Ruyang Yu,Qilyu Zhou,Ping Liu,Zhongjie Liu,Yifei Bian

DOI: https://doi.org/10.1039/d1fo00155h

IF: 6.3173

2021-01-01

Food & Function

Abstract:The microvasculature endothelium accurately regulates the passage of molecules across the gut-vascular barrier (GVB), which plays an essential role in intestinal immunity. Naringenin is reported to have therapeutic potential against several intestinal disorders. However, the effect of naringenin on GVB disruption has been rarely studied. This study aims to investigate the effect of naringenin on GVB function and the potential mechanism. In the present study, the in vitro GVB disruption of rat intestinal microvascular endothelial cells (RIMVEC) was induced by 50 ng mL-1 of tumor necrosis factor-α (TNF-α). The integrity of the in vitro GVB was determined by Evans blue (EB)-albumin efflux assay and trans-endothelial electrical resistance (TER). Meanwhile, the expression of tight junction proteins and the related NF-κB, MLCK/p-MLC and NLRP3 pathways were determined using enzyme-linked immunosorbent assay (ELISA), real-time quantitative polymerase chain reaction (RT-qPCR), western blot analysis and immunofluorescence. The results show that naringenin (100 μM) inhibits TNF-α-induced interleukin (IL)-6 hypersecretion, alleviates GVB disruption and mitigates the change in the tight junction protein expression pattern. Naringenin inhibits the GVB-disruption-associated activation of the MLCK/p-MLC system and TLR4/NF-κB/NLRP3 pathways. Furthermore, naringenin shows a similar effect to that of NF-κB inhibitor Bay 11-7082 in reducing the TNF-α-induced activation of NLRP3, p-MLC and secondary GVB disruption. The results suggest that naringenin evidently alleviates TNF-α-induced in vitro GVB disruption via the maintenance of a tight junction protein pattern, partly with the inhibition of the NF-κB-mediated MLCK/p-MLC and NLRP3 pathway activation.
Naringin protects against inflammation and apoptosis induced by intestinal ischemia–reperfusion injury through deactivation of cGAS‐STING signaling pathway

Lidan Gu,Fei Wang,Yilin Wang,Deen Sun,Yiming Sun,Tingting Tian,Qiang Meng,Lianhong Yin,Lina Xu,Xiaolong Lu,Jinyong Peng,Yuan Lin,Pengyuan Sun

DOI: https://doi.org/10.1002/ptr.7824

IF: 6.388

2023-05-03

Phytotherapy Research

Abstract:Effective amelioration of ischemia/reperfusion (I/R)‐induced intestinal injury and revealing its mechanisms remain the challenges in both preclinic and clinic. Potential mechanisms of naringin in ameliorating I/R‐induced intestinal injury remain unknown. Based on pre‐experiments, I/R‐injured rat intestine in vivo and hypoxia–reoxygenation (H/R)‐injured IEC‐6 cells in vitro were used to verify that naringin‐alleviated I/R‐induced intestinal injury was mediated via deactivating cGAS‐STING signaling pathway. Naringin improved intestinal damage using hematoxylin and eosin staining and decreased alanine aminotransferase and aspartate aminotransferase contents in plasma. Naringin decreased inflammation characterized by reducing IL‐6, IL‐1β, TNF‐α, and IFN‐β contents in both plasma and IEC‐6 cells. Naringin mitigated oxidative stress via recovering superoxide dismutase, glutathione, and malondialdehyde levels in the I/R‐injured intestine. Naringin reduced the expression of apoptotic proteins, including Bax, caspase‐3, and Bcl‐2, and reduced terminal deoxynucleotidyl transferase‐mediated dUTP‐biotin nick‐end labeling‐positive cells both in vivo and in vitro, and decreased Hoechst 33342 signals in vitro. cGAS, STING, p‐TBK1, p‐IRF3, and NF‐κB expressions were up‐regulated both in vivo and in vitro respectively and the up‐regulated indexes were reversed by naringin. Transfection of cGAS‐siRNA and cGAS‐cDNA significantly down‐regulated and up‐regulated cGAS‐STING signaling‐related protein expressions, respectively, and partially weakened naringin‐induced amelioration on these indexes, suggesting that deactivation of cGAS‐STING signaling is the crucial target for naringin‐induced amelioration on I/R‐injured intestine.

pharmacology & pharmacy,chemistry, medicinal
Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling.

Wei Dou,Jingjing Zhang,Aning Sun,Eryun Zhang,Lili Ding,Subhajit Mukherjee,Xiaohui Wei,Guixin Chou,Zheng-Tao Wang,Sridhar Mani

DOI: https://doi.org/10.1017/S0007114512005594

2013-01-01

British Journal Of Nutrition

Abstract:Naringenin, one of the most abundant flavonoids in citrus, grapefruits and tomatoes, has been used as a traditional anti-inflammatory agent for centuries. However, the molecular mechanism of naringenin in intestinal inflammation remains unknown so far. The present study investigated a molecular basis for the protective effect of naringenin in dextran sulphate sodium-induced murine colitis. Pre-administration of naringenin significantly reduced the severity of colitis and resulted in down-regulation of pro-inflammatory mediators (inducible NO synthase (iNOS), intercellular adhesion molecule-1 (ICAM-1), monocyte chemoattractant protein-1 (MCP-1), cyclo-oxygenase-2 (Cox2), TNF-alpha and IL-6 mRNA) in the colon mucosa. The decline in the production of pro-inflammatory cytokines, specifically TNF-alpha and IL-6, correlated with a decrease in mucosal Toll-like receptor 4 (TLR4) mRNA and protein. Phospho-NF-kappa B p65 protein was significantly decreased, which correlated with a similar decrease in phospho-I kappa B alpha protein. Consistent with the in vivo results, naringenin exposure blocked lipopolysaccharide-stimulated nuclear translocation of NF-kappa B p65 in mouse macrophage RAW264.7 cells. In addition, in vitro NF-kappa B reporter assays performed on human colonic HT-29 cells exposed to naringenin demonstrated a significant inhibition of TNF-alpha-induced NF-kappa B luciferase expression. Thus, for the first time, the present study indicates that targeted inhibition of the TLR4/NF-kappa B signalling pathway might be an important mechanism for naringenin in abrogating experimental colitis.
Naringenin Prevents Oxidative Stress and Inflammation in LPS-Induced Liver Injury through the Regulation of LncRNA-mRNA in Male Mice

Mengting Ji,Zhao Deng,Xiaoyin Rong,Ruixiao Li,Ziwei You,Xiaohong Guo,Chunbo Cai,Yan Zhao,Pengfei Gao,Guoqing Cao,Bugao Li,Yang Yang

DOI: https://doi.org/10.3390/molecules28010198

IF: 4.6

2022-12-27

Molecules

Abstract:Inflammation accompanies hepatic dysfunction resulting from tissue oxidative damage. Naringenin (Nar), a natural flavanone, has known antioxidant and anti-inflammatory activities, but its mechanism of action in the regulation of liver dysfunction requires further investigation. In this study, the role of naringenin in lipopolysaccharide (LPS)-induced hepatic oxidative stress and inflammation was explored, as well as its mechanism by transcriptome sequencing. The results indicated that compared with the LPS group, Nar treatment caused a significant increase in the mRNA levels of antioxidant factors glutamate-cysteine ligase catalytic subunit (GCLC) and glutamate-cysteine ligase modifier subunit (GCLM), yet the expression of related inflammatory factors (MCP1, TNFα, IL-1β and IL-6) showed less of an increase. RNA sequencing identified 36 differentially expressed lncRNAs and 603 differentially expressed mRNAs. KEGG enrichment analysis indicated that oxidative stress and inflammation pathways are meticulously linked with naringenin treatment. The Co-lncRNA-mRNA network was also constructed. Tissue expression profiles showed that lncRNA played a higher role in the liver. Subsequently, expression levels of inflammatory factors indicated that lncRNAs and target mRNAs were significantly reduced after naringenin treatment in mouse liver AML12 cells and obese mouse. These results suggest that naringenin helps to prevent liver dysfunction through the regulation of lncRNA-mRNA axis to reduce oxidative stress and inflammatory factors.

chemistry, multidisciplinary,biochemistry & molecular biology
Naringenin Prevents NAFLD in the Diet-Induced C57BL/6J Obesity Model by Regulating the Intestinal Barrier Function and Microbiota

Ruyang Yu,Yinping Gu,Lanyan Zheng,Zhongjie Liu,Yifei Bian

DOI: https://doi.org/10.1016/j.jff.2023.105578

IF: 5.6

2023-01-01

Journal of Functional Foods

Abstract:Objectives: The intestinal immunity and the microbiota play an essential role in metabolic syndrome associated with obesity, for instance, non-alcoholic fatty liver disease (NAFLD). However, the effects of naringenin on diet-induced NAFLD and intestinal functions have not been reported. Methods: The effects of naringenin on NAFLD were assessed in C57BL/6J administrated with a high-fat diet (HFD) and high-fat diet with 0.1% naringenin (HFN). The ELISA, histopathology, and flow cytometry were conducted to assess the effects of naringenin on the liver and intestinal inflammation. The FITC-dextran, western blot, and real-time quantitative PCR were used to evaluate the effects of naringenin on intestinal permeability. The regulatory effects of naringenin on intestinal microbiota in NAFLD mice were detected by 16S rRNA sequencing. Results: Naringenin could curb weight gain in obese mice, reduce the content of triglyceride (TG) and total cholesterol (TC) in blood and liver, and even improve the steatosis of liver cells. Naringenin alleviated the rate of infiltration in dendritic cells and macrophages in colon tissues and inhibited inflammatory factors in the intestinal and liver tissues. Naringenin reduced the gut barrier permeability caused by HFD and increased the expression of tight junction proteins (TJs). Furthermore, naringenin significantly improved the cecal microbiota disorder by enhancing the growth of salutary symbiotic bacteria and restraining the colonization of pathogenic bacteria. Conclusion: Naringenin could relieve metabolic disorders caused by HFD and improve gut barrier functions, thereby inhibiting the migration of intestinal microorganisms and products via the gut-liver axis, thus preventing NAFLD.
Protective Effect of Naringin on in Vitro Gut-Vascular Barrier Disruption of Intestinal Microvascular Endothelial Cells Induced by TNF-α.

Ping Liu,Yifei Bian,Yingsai Fan,Jia Zhong,Zhongjie Liu

DOI: https://doi.org/10.1021/acs.jafc.9b06347

IF: 6.1

2019-01-01

Journal of Agricultural and Food Chemistry

Abstract:Naringin is a polymethoxylated flavonoid commonly found in citrus species and has therapeutic potential in intestinal disorders. However, the effect and mechanism of naringin on gut-vascular barrier disruption has not yet been reported. This study aimed to investigate the distinguishing and selectively protective effects of naringin on tumor necrosis factor (TNF)-α-induced gut-vascular barrier disruption and elucidate the potential mechanism. In the present study, an in vitro gut-vascular barrier model composed of rat intestinal microvascular endothelial cells (RIMVECs) was studied. Evans blue-albumin efflux assay showed that naringin (50 μM) evidently protected the integrity of RIMVEC monolayer barriers against TNF-α-induced disruption. Naringin maintained the expression and distribution of tight junction proteins including zona occludin-1, occludin, claudin-1, and claudin-2. Additionally, naringin protected RIMVECs from TNF-α-induced apoptosis and cell migration suppression (41.1 ± 2.2 vs 51.1 ± 3.5%; 61.0 ± 5.1 vs 72.2 ± 6.2%). Our results indicate that naringin effectively ameliorates gut-vascular barrier disruption.
L-Cysteine Protects Intestinal Integrity, Attenuates Intestinal Inflammation And Oxidant Stress, And Modulates Nf-B And Nrf2 Pathways In Weaned Piglets After Lps Challenge

Ze he Song,Guo Tong,Kan Xiao,Le fei Jiao,Ya lu Ke,Cai hong Hu

DOI: https://doi.org/10.1177/1753425916632303

2016-01-01

Innate Immunity

Abstract:In this study we investigated whether L-cysteine (L-cys) could alleviate LPS-induced intestinal disruption and its underlying mechanism. Piglets fed with an L-cys-supplemented diet had higher average daily gain. L-cys alleviated LPS-induced structural and functional disruption of intestine in weanling piglets, as demonstrated by higher villus height, villus height (VH) to crypt depth (CD) ratio, and transepithelial electrical resistance (TER) and lower FITC-dextran 4 (FD4) kDa flux in jejunum and ileum. Supplementation with L-cys up-regulated occludin and claudin-1 expression, reduced caspase-3 activity and enhanced proliferating cell nuclear antigen expression of jejunum and ileum relative to LPS group. Additionally, L-cys suppressed the LPS-induced intestinal inflammation and oxidative stress, as demonstrated by down-regulated TNF-, IL-6 and IL-8 mRNA levels, increased catalase, superoxide dismutase, glutathione peroxidase activity, glutathione (GSH) contents and the ratio of GSH and oxidized glutathione in jejunum and ileum. Finally, a diet supplemented with L-cys inhibited NF-B(p65) nuclear translocation and elevated NF erythroid 2-related factor 2 (Nrf2) translocation compared with the LPS group. Collectively, our results indicated the protective function of L-cys on intestinal mucosa barrier may closely associated with its anti-inflammation, antioxidant and regulating effect on the NF-B and Nrf2 signaling pathways.
Naringin Inhibits Chemokine Production in an LPS-induced RAW 264.7 Macrophage Cell Line.

Ying Liu,Wei-Wei Su,Sheng Wang,Pei-Bo Li

DOI: https://doi.org/10.3892/mmr.2012.1072

IF: 3.423

2012-01-01

Molecular Medicine Reports

Abstract:Naringin has been reported to act as an effective anti-inflammatory compound. In a previous study, we demonstrated that the anti-inflammatory effect of naringin on lipopolysaccharide (LPS)-induced acute lung injury in mice correlated with the inhibition of the nuclear factor-kappa B (NF-kappa B) pathway. However, the effects and mechanism of action of naringin on LPS-induced chemokine expression are not yet fully understood. This study aimed to evaluate the effect of naringin on chemokine expression in LPS-induced RAW 264.7 macrophages and to provide insights into the possible underlying mechanisms. We found that the in vitro pre-treatment with naringin led to a significant attenuation in the LPS-induced secretion of interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-la (MIP-1 alpha). RT-qPCR demonstrated that naringin significantly reduced the LPS-induced upregulation of IL-8, MCP-1 and MIP-1 alpha mRNA expression in a dose-dependent manner. Additionally, western blot analysis revealed that naringin effectively suppressed NF-kappa B activation by inhibiting the degradation of I kappa B-alpha and the translocation of p65. Naringin also attenuated MAPK activation by inhibiting the phosphorylation of ERK1/2, JNK and p38 MAPK. Taken together, these demonstrate that naringin reduces IL-8, MCP-I and MIP-1 alpha secretion and mRNA expression, possibly by blocking the activation of the NF-kappa B and MAPK signaling pathways in LPS-induced RAW 264.7 macrophages.
Naringin Attenuates High Fat Diet Induced Non-alcoholic Fatty Liver Disease and Gut Bacterial Dysbiosis in Mice

Hongna Mu,Qi Zhou,Ruiyue Yang,Jie Zeng,Xianghui Li,Ranran Zhang,Weiqing Tang,Hongxia Li,Siming Wang,Tao Shen,Xiuqing Huang,Lin Dou,Jun Dong

DOI: https://doi.org/10.3389/fmicb.2020.585066

IF: 5.2

2020-01-01

Frontiers in Microbiology

Abstract:The incidence of non-alcoholic fatty liver disease (NAFLD) is rising annually, and emerging evidence suggests that the gut bacteria plays a causal role in NAFLD. Naringin, a natural flavanone enriched in citrus fruits, is reported to reduce hepatic lipid accumulation, but to date, no investigations have examined whether the benefits of naringin are associated with the gut bacteria. Thus, we investigated whether the antilipidemic effects of naringin are related to modulating the gut bacteria and metabolic functions. In this study, C57BL/6J mice were fed a high-fat diet (HFD) for 8 weeks, then fed an HFD with or without naringin administration for another 8 weeks. Naringin intervention reduced the body weight gain, liver lipid accumulation, and lipogenesis and attenuated plasma biochemical parameters in HFD-fed mice. Gut bacteria analysis showed that naringin altered the community compositional structure of the gut bacteria characterized by increased benefits and fewer harmful bacteria. Additionally, Spearman’s correlation analysis showed that at the genus level, Allobaculum, Alloprevotella, Butyricicoccus, Lachnospiraceae_NK4A136_group, Parasutterella and uncultured_bacterium_f_Muribaculaceae were negatively correlated and Campylobacter, Coriobacteriaceae_UCG-002, Faecalibaculum and Fusobacterium were positively correlated with serum lipid levels. These results strongly suggest that naringin may be used as a potential agent to prevent gut dysbiosis and alleviate NAFLD.
Naringin Inhibits Lipopolysaccharide-Induced Activation of Microglia Cells.

Jie Bai,Siyuan Li,Gang Wu,Lei Ma,Chen Li,Hongtao Liu,Pengbo Zhang

DOI: https://doi.org/10.14715/cmb/2019.65.5.6

2019-01-01

Cellular and Molecular Biology

Abstract:The purpose of this study was to investigate the effect of naringin on lipopolysaccharide (LPS)-induced activation of BV2 microglia and inflammatory factor release, and the mechanism involved. Different concentrations of naringin were used to pretreat BV2 cells for 30 min, after which they were stimulated with 100 ng/mL LPS for different durations. The levels of NO, IL-1β and TNF-α in the cell culture medium was determined with ELISA and Griess method. The mRNA expressions of IL-1β and TNF-α was determined with RT-PCR. Changes in ERK and p65/NF-κB signaling pathway proteins were assayed with Western blotting. After 12 h stimulation of BV2 cells with LPS, the levels of IL-1β and TNF-α in the cell culture medium were significantly increased, but naringin had no significant effect on these inflammatory factors. In the cells pretreated with naringin, LPS stimulated the activation of microglia to produce IL-1β and TNF-α in a dose-dependent manner. Naringin inhibited LPS-induced release of IL-1β, to a certain extent. The TNF-α gene was overexpressed. In addition, LPS stimulated a dose-dependent decrease in NO production by BV2 after pretreatment with different concentrations of naringin. Naringin pretreatment of cells significantly inhibited the activation of p65/NF-κB in a concentration-dependent manner. In BV2 microglia, naringin inhibits LPO-induced production of NO and inflammatory factors, through a mechanism involving inhibition of activation of the p65/NF-κB signaling pathway.
Ginsenoside Rg1 Mitigates Porcine Intestinal Tight Junction Disruptions Induced by LPS through the p38 MAPK/NLRP3 Inflammasome Pathway

Jian Kang,Yanhong Zhou,Chunyang Zhu,Tian Ren,Yong Zhang,Longfei Xiao,Binghu Fang

DOI: https://doi.org/10.3390/toxics10060285

2022-05-27

Toxics

Abstract:Inflammation leads to porcine tight junction disruption of small intestinal epithelial cells, resulting in intestinal dysfunction. Herein, we established lipopolysaccharide (LPS)-induced in-vivo and in-vitro inflammatory models. The results revealed that LPS induced tight junction disruption in IPEC-J2 cells by downregulating tight-junction-related protein zonula occludens-1 (ZO-1), occludin and claudin-1 expression, while ginsenoside Rg1 rescued such inhibition and abrogated the upregulated expression of phosphorylation p38 MAPK. The p38 MAPK inhibitor (SB203580) showed a similar effect with Rg1 and attenuated the LPS-induced inhibition of ZO-1, occludin and claudin-1 expression, which is consistent with the reduced expression of NLRP3 inflammasome and IL-1β. Furthermore, the specific inhibitors of NLRP3 and IL-1β result in increased expression of tight-junction-related protein, demonstrating that p38 MAPK signaling was associated with Rg1 suppression of tight junction disruption. Besides, LPS treatment decreased the expression of ZO-1, occludin and claudin-1 through p38 MAPK signaling, and caused abnormal morphological changes in murine ileum. Meanwhile, Rg1 attenuated the decreased expression of ZO-1, occludin and claudin-1 and partially alleviated LPS-induced morphological changes in murine ileum. In summary, these findings characterized a novel mechanism by which Rg1 alleviates LPS-induced intestinal tight junction disruption by inhibiting the p38 MAPK-mediated NLRP3 inflammasome pathway.

environmental sciences,toxicology
Naringenin Attenuates Non‐alcoholic Fatty Liver Disease by Down‐regulating the NLRP3/NF‐κB Pathway in Mice

Qinyu Wang,Yangjie Ou,Guomin Hu,Cong Wen,Shanshan Yue,Cong Chen,Lu Xu,Jiawei Xie,Hui Dai,Han Xiao,Youyi Zhang,Rong Qi

DOI: https://doi.org/10.1111/bph.14938

IF: 7.3

2020-01-01

British Journal of Pharmacology

Abstract:Background and PurposeNaringenin, a flavonoid compound with strong anti‐inflammatory activity, attenuated non‐alcoholic fatty liver disease (NAFLD) induced by a methionine‐choline deficient (MCD) diet in mice. However, the mechanisms underlying this suppression of inflammation and NAFLD remain unknown.Experimental ApproachWT and NLRP3−/− mice were fed with MCD diet for 7 days to induce NAFLD and were given naringenin by gavage at the same time. in vitro experiments used HepG2 cells, primary hepatocytes, and Kupffer cells (KCs) stimulated by LPS or LPS plus oleic acid (OA).Key ResultsTreating WT mice with naringenin (100 mg·kg−1·day−1) attenuated hepatic lipid accumulation and inflammation in the livers of mice given the MCD diet. NLRP3−/− mice showed less hepatic lipid accumulation than WT mice, but naringenin did not ameliorate hepatic lipid accumulation further in NLRP3−/− mice. Treating the HepG2 cells with naringenin or NLRP3 inhibitor MCC950 reduced lipid accumulation. Naringenin inhibited activation of the NLRP3/NF‐κB pathway stimulated by OA together with LPS. In KCs isolated from WT mice, naringenin inhibited NLRP3 expression. Naringenin also inhibited lipid deposition, NLRP3 and IL‐1β expression in WT hepatocytes but was not effective in NLRP3−/− hepatocytes. After re‐expressing NLRP3 in NLRP3−/− hepatocytes by adenovirus, the anti‐lipid deposition effect of naringenin was restored.Conclusion and ImplicationsNaringenin prevented NAFLD via down‐regulating the NLRP3/NF‐κB signalling pathway both in KCs and in hepatocytes, thus attenuating inflammation in the mice livers.
Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling

Xu Yan,Tianjiao Lin,Qingyun Zhu,Yushi Zhang,Zhimin Song,Xinting Pan

DOI: https://doi.org/10.3389/fphar.2023.1090261

IF: 5.6

2023-01-14

Frontiers in Pharmacology

Abstract:Background: In this study, we examined the functions and mechanisms by which naringenin protects against SAP (severe acute pancreatitis)-related intestinal injury by modulating the AhR/NLRP3 signaling pathway. Material and methods: Fifteen healthy male C57BL/6 mice were randomly divided into SAP ( n = 12) and normal ( n = 3) groups. Mice in the SAP group received caerulein and lipopolysaccharide intraperitoneal injections and were then randomly assigned to the SAP, NAR, CH223191, and Dexamethasone (DEX) groups. Pathological changes in the pancreatic and intestinal mucosa were observed by Hematoxylin & Eosin (H&E) staining. In vitro , RAW264.7 cells were exposed to lipopolysaccharide and treated with naringenin. The levels of NLRP3, AhR, IL-1β, TNF, and IL-6 in the SAP model and RAW264.7 cells were evaluated by enzyme-linked immunosorbent assay (ELISA), quantitative real-time PCR (qRT-PCR), western blot, and immunohistochemistry. The nuclear translocation of AhR was shown by immunofluorescence. AutoDockTools was used to predict the conformations of naringenin-AhR binding, and PyMol 2.4 was used to visualize the conformations. Results: Mouse pancreatic and intestinal injury was alleviated by treatment with naringenin. Naringenin inhibited the activation of the NLRP3 inflammasome and inhibited damage to intestinal tight junctions. Moreover, naringenin increased AhR nuclear translocation and activated the AhR pathway. Conclusion: Naringenin can reduce SAP-associated intestinal injury by inhibiting the activation of the NLRP3 inflammasome via the AhR signaling pathway.

pharmacology & pharmacy

Naringin Mitigates LPS-induced Intestinal Barrier Injury in Mice.

Naringin Exhibited Therapeutic Effects against DSS-Induced Mice Ulcerative Colitis in Intestinal Barrier–Dependent Manner

Mucoactive effects of naringin in lipopolysaccharide-induced acute lung injury mice and beagle dogs.

Naringin attenuates MLC phosphorylation and NF-κB activation to protect sepsis-induced intestinal injury via RhoA/ROCK pathway.

Naringin Attenuates Acute Lung Injury in LPS-treated Mice by Inhibiting NF-κB Pathway.

Protective Effect of Naringin on DSS-Induced Ulcerative Colitis in Mice.

Protective Effects of Naringin Against Paraquat-Induced Acute Lung Injury and Pulmonary Fibrosis in Mice

Naringin Exerts Therapeutic Effects on Mice Colitis: A Study Based on Transcriptomics Combined With Functional Experiments

Naringenin Prevents TNF-α-induced Gut-Vascular Barrier Disruption Associated with Inhibiting the NF-κB-mediated MLCK/p-MLC and NLRP3 Pathways

Naringin protects against inflammation and apoptosis induced by intestinal ischemia–reperfusion injury through deactivation of cGAS‐STING signaling pathway

Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling.

Naringenin Prevents Oxidative Stress and Inflammation in LPS-Induced Liver Injury through the Regulation of LncRNA-mRNA in Male Mice

Naringenin Prevents NAFLD in the Diet-Induced C57BL/6J Obesity Model by Regulating the Intestinal Barrier Function and Microbiota

Protective Effect of Naringin on in Vitro Gut-Vascular Barrier Disruption of Intestinal Microvascular Endothelial Cells Induced by TNF-α.

L-Cysteine Protects Intestinal Integrity, Attenuates Intestinal Inflammation And Oxidant Stress, And Modulates Nf-B And Nrf2 Pathways In Weaned Piglets After Lps Challenge

Naringin Inhibits Chemokine Production in an LPS-induced RAW 264.7 Macrophage Cell Line.

Naringin Attenuates High Fat Diet Induced Non-alcoholic Fatty Liver Disease and Gut Bacterial Dysbiosis in Mice

Naringin Inhibits Lipopolysaccharide-Induced Activation of Microglia Cells.

Ginsenoside Rg1 Mitigates Porcine Intestinal Tight Junction Disruptions Induced by LPS through the p38 MAPK/NLRP3 Inflammasome Pathway

Naringenin Attenuates Non‐alcoholic Fatty Liver Disease by Down‐regulating the NLRP3/NF‐κB Pathway in Mice

Naringenin protects against acute pancreatitis-associated intestinal injury by inhibiting NLRP3 inflammasome activation via AhR signaling